Comparative Analyses of Complex Formation and Binding Sites between Human Tumor Necrosis Factor-alpha and its Three Antagonists Elucidate their Different Neutralizing Mechanisms

Journal of Molecular Biology

Volumn 374, Issue 5, 2007, Pages 1374-1388

  Kim, Min Soo ^a   Lee, Seung Hyun ^a   Song, Moo Young ^b   Yoo, Tae Hyoung ^b   Lee, Byung Kyu ^b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Yuhan Corporation   (South Korea)

Author keywords

binding site analysis; binding stoichiometry; soluble complex; TNF ; TNF antagonist

Indexed keywords

ETANERCEPT; INFLIXIMAB; MONCLONAL ANTIBODY YHB1411 2; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; COMPLEX FORMATION; DRUG BINDING; DRUG BINDING SITE; DRUG MECHANISM; DRUG STABILITY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; STOICHIOMETRY; THERMODYNAMICS;

EID: 36249007492     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.10.034     Document Type: Article

References (33)

1. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev. Immunol. 2 (2002) 364-371
2. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36 (2006) 159-167
3. Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr. Opin. Struct. Biol. 14 (2004) 154-160
4. Eck M.J., and Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6 Å resolution. Implications for receptor binding. J. Biol. Chem. 264 (1989) 17595-17605
5. Winterfield L.S., and Menter A. Infliximab. Dermatol. Ther. 17 (2004) 409-426
6. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30 (1993) 1443-1453
7. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151 (1993) 1548-1561
8. Goffe B., and Cather J.C. Etanercept: an overview. J. Am. Acad. Dermatol. 49 (2003) S105-S111
9. Santora L.C., Kaymakcalan Z., Sakorafas P., Krull I.S., and Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal. Biochem. 299 (2001) 119-129
10. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., and Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301 (2002) 418-426
11. Shoji-Hosaka E., Kobayashi Y., Wakitani M., Uchida K., Niwa R., Nakamura K., and Shitara K. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J. Biochem. (Tokyo) 140 (2006) 777-783
12. Goldsby R.A., Kindt T.J., Osborne B.A., and Kuby J. Antigen-antibody interactions: principles and applications. Immunology. 5th edit. (2003), Freeman, New York 137-160
13. Liu J., Lester P., Builder S., and Shire S.J. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34 (1995) 10474-10482
14. Kim Y.S., Bhandari R., Cochran J.R., Kuriyan J., and Wittrup K.D. Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins: Struct. Funct. Genet. 62 (2006) 1026-1035
15. Chao G., Cochran J.R., and Wittrup K.D. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J. Mol. Biol. 342 (2004) 539-550
16. Cochran J.R., Kim Y.S., Olsen M.J., Bhandari R., and Wittrup K.D. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J. Immunol. Methods 287 (2004) 147-158
17. Lee H.W., Lee S.H., Park K.J., Kim J.S., Kwon M.H., and Kim Y.S. Construction and characterization of a pseudo-immune human antibody library using yeast surface display. Biochem. Biophys. Res. Commun. 346 (2006) 896-903
18. Levy R., Forsyth C.M., LaPorte S.L., Geren I.N., Smith L.A., and Marks J.D. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol. 365 (2007) 196-210
19. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312 (1984) 724-729
20. Van Ostade X., Tavernier J., Prange T., and Fiers W. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J. 10 (1991) 827-836
21. Van Ostade X., Tavernier J., and Fiers W. Structure-activity studies of human tumour necrosis factors. Protein Eng. 7 (1994) 5-22
22. Tavernier J., Marmenout A., Bauden R., Hauquier G., Van Ostade X., and Fiers W. Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis. J. Mol. Biol. 211 (1990) 493-501
23. Yamagishi J., Kawashima H., Matsuo N., Ohue M., Yamayoshi M., Fukui T., et al. Mutational analysis of structure-activity relationships in human tumor necrosis factor-alpha. Protein Eng. 3 (1990) 713-719
24. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73 (1993) 431-445
25. Gase K., Korobko V.G., Wisniewski H.G., Le J., Dobrynin V.N., Filippov S.A., et al. Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha. Immunology 71 (1990) 368-371
26. Sundberg E.J., and Mariuzza R.A. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61 (2002) 119-160
27. Khabar K.S., Siddiqui S., and Armstrong J.A. WEHI-13VAR: a stable and sensitive variant of WEHI 164 clone 13 fibrosarcoma for tumor necrosis factor bioassay. Immunol. Letters 46 (1995) 107-110
28. Ferrant J.L., Wilson C.A., Benjamin C.D., Hess D.M., Hsu Y.M., Karpusas M., et al. Variation in the ordered structure of complexes between CD154 and anti-CD154 monoclonal antibodies. Mol. Immunol. 39 (2002) 77-84
29. Van Ostade X., Vandenabeele P., Tavernier J., and Fiers W. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur. J. Biochem. 220 (1994) 771-779
30. Kim Y.R., Kim J.S., Lee S.H., Lee W.R., Sohn J.N., Chung Y.C., et al. Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity. J. Biol. Chem. 281 (2006) 15287-15295
31. Laue T.M. Sedimentation equilibrium as thermodynamic tool. Methods Enzymol. 259 (1995) 427-452
32. Lee H.W., Lee S.H., Lee H.W., Ryu Y.W., Kwon M.H., and Kim Y.S. Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem. Biophys. Res. Commun. 330 (2005) 1205-1212
33. Park K.J., Lee S.H., Kim T.I., Lee H.W., Lee C.H., Kim E.H., et al. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res. 67 (2007) 7327-7334